50+ total transactions representing $350M+ in aggregate value — 8 tracked below spanning 2018–2025 · 3 industries
Take-private sale of Enzo Biochem to Battery Ventures following comprehensive strategic review by special committee. Enzo is a life sciences company providing labeling, detection technologies, antibodies, genomic probes, and assays for translational research and drug development. BroadOak advised the special committee through the transaction process.
Sale of Omixon, a privately-held developer of innovative transplant diagnostics solutions based in Budapest, Hungary, to Werfen (Barcelona-based healthcare company). Omixon provides NGS-based HLA typing and transplant diagnostics. Transaction completed October 16, 2024 after obtaining regulatory approvals.
Sale of Edge BioSystems, a specialized manufacturer and distributor of sample preparation and clean-up systems for laboratories, to StoneCalibre (Calibre Scientific portfolio company). BroadOak served as exclusive sell-side financial advisor. Transaction completed October 1, 2024.
Acquisition of MyChem LLC, a leader in proprietary ultra-pure nucleotides serving biopharma and vaccine manufacturers, by Maravai LifeSciences for $240M in cash. MyChem's products are critical inputs for therapeutics and vaccine manufacturing. This represents a flagship advisory transaction for BroadOak.
Acquisition of Lucigen Corporation, a leading developer and manufacturer of molecular biology enzymes, reagents, and kits, by LGC. Transaction strengthened LGC's reagents offering to the genomics market. Demonstrates BroadOak's long-standing advisory relationships in life sciences tools sector.
Divestiture of Genie Division, a laboratory equipment and incubation equipment business, to Troemner LLC (subsidiary of Mettler-Toledo). This strategic divestiture allowed Scientific Industries to refocus on data-driven business platforms. Transaction closed August 7, 2025.